Ji

Milestone Pharmaceuticals Announces Exclusive License Agreement with Ji Xing Pharmaceuticals to Develop and Commercialize Etripamil for PSVT in Greater China

Retrieved on: 
Monday, May 17, 2021
XING, Ji

"We look forward to partnering with the talented team at Ji Xing to develop and commercialize this promising therapy in the licensed regions.

Key Points: 
  • "We look forward to partnering with the talented team at Ji Xing to develop and commercialize this promising therapy in the licensed regions.
  • "We are delighted to expand Ji Xing\'s cardiovascular focus by partnering with Milestone and look forward to unlocking the full therapeutic potential of etripamil for patients with PSVT in China.
  • "\nUnder the terms of the agreement, Milestone will grant Ji Xing an exclusive license to develop and, if regulatory approval is obtained, commercialize etripamil in patients with PSVT in Greater China.
  • In addition, Milestone is eligible to receive up to $107.5 million in milestone payments and royalties on future sales of etripamil in Greater China.

Jicheng Lyu: The Philanthropic Prophet

Retrieved on: 
Saturday, March 20, 2021
Yan, Jicheng, Ji, YU

Jicheng Lyu opens on his lifetime of service, saying: "I have always believed that local and grassroots organizations are the catalyst to change."

Key Points: 
  • Jicheng Lyu opens on his lifetime of service, saying: "I have always believed that local and grassroots organizations are the catalyst to change."
  • Going deeper into what Jicheng Lyu and his team accomplished that led to the Philanthropy Award nomination, the journey includes aid for different branches of relief.
  • Fortunately, Jicheng Lyu knew he had to step up and provide help in every way he knew how.
  • Jicheng Lyu hopes so and plans to have a positive effect on those who wish to do good for the benefit of others.